{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:42:03Z","timestamp":1792813323827,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study compared the effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa; GONAL-f<jats:sup>\u00ae<\/jats:sup>) with urinary highly purified human menopausal gonadotropin (hMG HP; Menogon HP<jats:sup>\u00ae<\/jats:sup>), during assisted reproductive technology (ART) treatments in Germany.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were collected from 71 German fertility centres between 01 January 2007 and 31 December 2012<jats:bold>,<\/jats:bold> for women undergoing a first stimulation cycle of ART treatment with r-hFSH-alfa or hMG HP. Primary outcomes were live birth, ongoing pregnancy and clinical pregnancy, based on cumulative data (fresh and frozen-thawed embryo transfers), analysed per patient (pP), per complete cycle (pCC) and per first complete cycle (pFC). Secondary outcomes were pregnancy loss (analysed per clinical pregnancy), cancelled cycles (analysed pCC), total drug usage per oocyte retrieved and time-to-live birth (TTLB; per calendar week and per cycle).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-eight thousand six hundred forty-one women initiated a first treatment cycle (r-hFSH-alfa: 17,725 [61.9%]; hMG HP: 10,916 [38.1%]). After adjustment for confounding variables, treatment with r-hFSH-alfa versus hMG HP was associated with a significantly higher probability of live birth (hazard ratio [HR]-pP [95% confidence interval (CI)]: 1.10 [1.04, 1.16]; HR-pCC [95% CI]: 1.13 [1.08, 1.19]; relative risk [RR]-pFC [95% CI]: 1.09 [1.05, 1.15], ongoing pregnancy (HR-pP [95% CI]: 1.10 [1.04, 1.16]; HR-pCC [95% CI]: 1.13 [1.08, 1.19]; RR-pFC [95% CI]: 1.10 [1.05, 1.15]) and clinical pregnancy (HR-pP [95% CI]: 1.10 [1.05, 1.14]; HR-pCC [95% CI]: 1.14 [1.10, 1.19]; RR-pFC [95% CI]: 1.10 [1.06, 1.14]). Women treated with r-hFSH-alfa versus hMG HP had no statistically significant difference in pregnancy loss (HR [95% CI]: 1.07 [0.98, 1.17], were less likely to have a cycle cancellation (HR [95% CI]: 0.91 [0.84, 0.99]) and had no statistically significant difference in TTLB when measured in weeks (HR [95% CI]: 1.02 [0.97, 1.07]; <jats:italic>p<\/jats:italic>\u2009=\u20090.548); however, r-hFSH-alfa was associated with a significantly shorter TTLB when measured in cycles versus hMG HP (HR [95% CI]: 1.07 [1.02, 1.13]; <jats:italic>p<\/jats:italic>\u2009=\u20090.003). There was an average of 47% less drug used per oocyte retrieved with r-hFSH-alfa versus hMG HP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This large (&gt;\u200928,000 women), real-world study demonstrated significantly higher rates of cumulative live birth, cumulative ongoing pregnancy and cumulative clinical pregnancy with r-hFSH-alfa versus hMG HP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12958-021-00768-3","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T07:02:38Z","timestamp":1623826958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany"],"prefix":"10.1186","volume":"19","author":[{"given":"Klaus F.","family":"B\u00fchler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Verpillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Allignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Boutmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Bilger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u2019Hooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"768_CR1","volume-title":"Guideline on Ovarian Stimulation in IVF\/ICSI","author":"ESHRE","year":"2019","unstructured":"ESHRE. Guideline on Ovarian Stimulation in IVF\/ICSI. 2019. Available from: https:\/\/www.eshre.eu\/Guidelines-and-Legal\/Guidelines\/Ovarian-Stimulation-in-IVF-ICSI."},{"key":"768_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/09513590.2019.1650345","volume":"35","author":"B Lunenfeld","year":"2019","unstructured":"Lunenfeld B, Bilger W, Longobardi S, Kirsten J, D'Hooghe T, Sunkara SK. Decision points for individualized hormonal stimulation with recombinant gonadotropins for treatment of women with infertility. Gynecol Endocrinol. 2019;35:1027\u201336.","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"768_CR3","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.fertnstert.2018.04.037","volume":"109","author":"BW Mol","year":"2018","unstructured":"Mol BW, Bossuyt PM, Sunkara SK, Garcia Velasco JA, Venetis C, Sakkas D, et al. Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients. Fertil Steril. 2018;109(6):968\u201379. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.04.037.","journal-title":"Fertil Steril"},{"key":"768_CR4","volume-title":"CG156: Fertility problems: assessment and treatment","author":"National Institute for Health and Care Excellence","year":"2017","unstructured":"National Institute for Health and Care Excellence. CG156: Fertility problems: assessment and treatment 2017. Available from: https:\/\/www.nice.org.uk\/guidance\/cg156\/chapter\/Recommendations."},{"issue":"9","key":"768_CR5","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/humrep\/dex234","volume":"32","author":"F Zegers-Hochschild","year":"2017","unstructured":"Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The international glossary on infertility and fertility care, 2017. Hum Reprod. 2017;32(9):1786\u2013801. https:\/\/doi.org\/10.1093\/humrep\/dex234.","journal-title":"Hum Reprod"},{"key":"768_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3389\/fendo.2019.00429","volume":"10","author":"B Lunenfeld","year":"2019","unstructured":"Lunenfeld B, Bilger W, Longobardi S, Alam V, D'Hooghe T, Sunkara SK. The development of gonadotropins for clinical use in the treatment of infertility. Front Endocrinol. 2019;10:429.","journal-title":"Front Endocrinol"},{"issue":"2","key":"768_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.fertnstert.2018.06.005","volume":"110","author":"C Niederberger","year":"2018","unstructured":"Niederberger C, Pellicer A, Cohen J, Gardner DK, Palermo GD, O'Neill CL, et al. Forty years of IVF. Fertil Steril. 2018;110(2):185\u2013324.e5.","journal-title":"Fertil Steril"},{"issue":"3","key":"768_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00063030-199809030-00006","volume":"9","author":"KL Goa","year":"1998","unstructured":"Goa KL, Wagstaff AJ. Follitropin alpha in infertility: a review. BioDrugs. 1998;9(3):235\u201360. https:\/\/doi.org\/10.2165\/00063030-199809030-00006.","journal-title":"BioDrugs"},{"issue":"4","key":"768_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.6061\/clinics\/2014(04)10","volume":"69","author":"B Leao Rde","year":"2014","unstructured":"Leao Rde B, Esteves SC. Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. Clinics. 2014;69(4):279\u201393. https:\/\/doi.org\/10.6061\/clinics\/2014(04)10.","journal-title":"Clinics"},{"issue":"5","key":"768_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S1472-6483(10)62071-8","volume":"7","author":"BH van de Weijer","year":"2003","unstructured":"van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW. Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003;7(5):547\u201357.","journal-title":"Reprod Biomed Online"},{"issue":"6","key":"768_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1210\/edrv-16-6-765","volume":"16","author":"A Ulloa-Aguirre","year":"1995","unstructured":"Ulloa-Aguirre A, Midgley AR Jr, Beitins IZ, Padmanabhan V. Follicle-stimulating isohormones: characterization and physiological relevance. Endocr Rev. 1995;16(6):765\u201387. https:\/\/doi.org\/10.1210\/edrv-16-6-765.","journal-title":"Endocr Rev"},{"key":"768_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fendo.2018.00216","volume":"9","author":"GR Bousfield","year":"2018","unstructured":"Bousfield GR, May JV, Davis JS, Dias JA, Kumar TR. In vivo and in vitro impact of carbohydrate variation on human follicle-stimulating hormone function. Front Endocrinol. 2018;9:216.","journal-title":"Front Endocrinol"},{"key":"768_CR13","volume-title":"Fertility: assessment and treatment for people with fertility problems. Clinical guideline","author":"NCC-WCH","year":"2004","unstructured":"NCC-WCH. Fertility: assessment and treatment for people with fertility problems. Clinical guideline. London: RCOG Press; 2004."},{"issue":"2","key":"768_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/humrep\/deg088","volume":"18","author":"H Al-Inany","year":"2003","unstructured":"Al-Inany H, Aboulghar M, Mansour R, Serour G. Meta-analysis of recombinant versus urinary-derived FSH: an update. Hum Reprod. 2003;18(2):305\u201313. https:\/\/doi.org\/10.1093\/humrep\/deg088.","journal-title":"Hum Reprod"},{"key":"768_CR15","first-page":"1","volume-title":"Recombinant FSH as adjuvant in assisted reproduction: some data on the efficacy and efficiency of recombinant FSH urinary FSH","author":"I Larizgoitia","year":"2000","unstructured":"Larizgoitia I, Estrada MD, Garcia-Altes A. Recombinant FSH as adjuvant in assisted reproduction: some data on the efficacy and efficiency of recombinant FSH urinary FSH. Barcelona: Catalan Agency for Health Technology Assessment and Research (CAHTA); 2000. p. 1\u201316."},{"key":"768_CR16","first-page":"Cd005354","volume":"2","author":"M van Wely","year":"2011","unstructured":"van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;2:Cd005354.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"768_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1472-6483(10)60559-7","volume":"16","author":"HG Al-Inany","year":"2008","unstructured":"Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod BioMed Online. 2008;16(1):81\u20138. https:\/\/doi.org\/10.1016\/S1472-6483(10)60559-7.","journal-title":"Reprod BioMed Online"},{"issue":"2","key":"768_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/humrep\/dem305","volume":"23","author":"A Coomarasamy","year":"2008","unstructured":"Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23(2):310\u20135. https:\/\/doi.org\/10.1093\/humrep\/dem305.","journal-title":"Hum Reprod"},{"key":"768_CR19","first-page":"CD003973","volume":"1","author":"M Van Wely","year":"2003","unstructured":"Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2003;1:CD003973.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"768_CR20","doi-asserted-by":"publisher","first-page":"hoz008","DOI":"10.1093\/hropen\/hoz008","volume":"2019","author":"EM Bordewijk","year":"2019","unstructured":"Bordewijk EM, Mol F, van der Veen F, Van Wely M. Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis. Hum Reprod Open. 2019;2019(3):hoz008.","journal-title":"Hum Reprod Open"},{"issue":"1","key":"768_CR21","first-page":"57","volume":"42","author":"ME Parsanezhad","year":"2017","unstructured":"Parsanezhad ME, Jahromi BN, Rezaee S, Kooshesh L, Alaee S. The effect of four different gonadotropin protocols on oocyte and embryo quality and pregnancy outcomes in IVF\/ICSI cycles; a randomized controlled trial. Iran J Med Sci. 2017;42(1):57\u201365.","journal-title":"Iran J Med Sci"},{"issue":"4","key":"768_CR22","first-page":"238","volume":"6","author":"A Figen Turkcapar","year":"2013","unstructured":"Figen Turkcapar A, Seckin B, Onalan G, Ozdener T, Batioglu S. Human menopausal gonadotropin versus recombinant FSH in polycystic ovary syndrome patients undergoing in vitro fertilization. Int J Fertil Steril. 2013;6(4):238\u201343.","journal-title":"Int J Fertil Steril"},{"issue":"3","key":"768_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.fertnstert.2011.12.016","volume":"97","author":"P Devroey","year":"2012","unstructured":"Devroey P, Pellicer A, Nyboe Andersen A, Arce JC. Menopur in Gn RHACwSETTG. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97(3):561\u201371. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.12.016.","journal-title":"Fertil Steril"},{"issue":"7","key":"768_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3109\/09513590.2011.650742","volume":"28","author":"H Ye","year":"2012","unstructured":"Ye H, Huang G, Pei L, Zeng P, Luo X. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial. Gynecol Endocrinol. 2012;28(7):540\u20134. https:\/\/doi.org\/10.3109\/09513590.2011.650742.","journal-title":"Gynecol Endocrinol"},{"issue":"12","key":"768_CR25","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/humrep\/del284","volume":"21","author":"AN Andersen","year":"2006","unstructured":"Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21(12):3217\u201327. https:\/\/doi.org\/10.1093\/humrep\/del284.","journal-title":"Hum Reprod"},{"issue":"3","key":"768_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S0015-0282(02)03250-8","volume":"78","author":"European, Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating H","year":"2002","unstructured":"European, Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating H. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization\/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril. 2002;78(3):520\u20138.","journal-title":"Fertil Steril"},{"issue":"6","key":"768_CR27","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/humrep\/deg252","volume":"18","author":"Z Kilani","year":"2003","unstructured":"Kilani Z, Dakkak A, Ghunaim S, Cognigni GE, Tabarelli C, Parmegiani L, et al. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod. 2003;18(6):1194\u20139. https:\/\/doi.org\/10.1093\/humrep\/deg252.","journal-title":"Hum Reprod"},{"issue":"6","key":"768_CR28","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.fertnstert.2007.05.039","volume":"89","author":"PG Hompes","year":"2008","unstructured":"Hompes PG, Broekmans FJ, Hoozemans DA, Schats R, Group F. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril. 2008;89(6):1685\u201393. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.05.039.","journal-title":"Fertil Steril"},{"issue":"10","key":"768_CR29","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1093\/humrep\/den220","volume":"23","author":"E Bosch","year":"2008","unstructured":"Bosch E, Vidal C, Labarta E, Simon C, Remohi J, Pellicer A. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study. Hum Reprod. 2008;23(10):2346\u201351. https:\/\/doi.org\/10.1093\/humrep\/den220.","journal-title":"Hum Reprod"},{"issue":"3","key":"768_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.rbmo.2016.11.010","volume":"34","author":"E Hershkop","year":"2017","unstructured":"Hershkop E, Segal L, Fainaru O, Kol S. \u2018Model\u2019 versus \u2018everyday\u2019 patients: can randomized controlled trial data really be applied to the clinic? Reprod BioMed Online. 2017;34(3):274\u20139. https:\/\/doi.org\/10.1016\/j.rbmo.2016.11.010.","journal-title":"Reprod BioMed Online"},{"key":"768_CR31","first-page":"149","volume":"27","author":"S Harari","year":"2018","unstructured":"Harari S. Randomised controlled trials and real-life studies: two answers for one question. Eur Respir Rev. 2018;27:149.","journal-title":"Eur Respir Rev"},{"issue":"5","key":"768_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","volume":"10","author":"LP Garrison Jr","year":"2007","unstructured":"Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10(5):326\u201335. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00186.x.","journal-title":"Value Health"},{"key":"768_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/JMDH.S160029","volume":"11","author":"VB Katkade","year":"2018","unstructured":"Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295\u2013304. https:\/\/doi.org\/10.2147\/JMDH.S160029.","journal-title":"J Multidiscip Healthc"},{"key":"768_CR34","volume-title":"EU lawmakers: Commission should weigh in on real world data","author":"Environment Public Health and Food Safety Committee","year":"2019","unstructured":"Environment Public Health and Food Safety Committee. EU lawmakers: Commission should weigh in on real world data 2019 Available from: https:\/\/www.politico.eu\/pro\/eu-lawmakers-commission-should-weigh-in-on-real-world-data\/?utm_source=POLITICO.EU&utm_campaign=a2cb793a46-EMAIL_CAMPAIGN_2019_12_03_12_41&utm_medium=email&utm_term=0_10959edeb5-a2cb793a46-190272561."},{"issue":"1","key":"768_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.rbmo.2017.10.102","volume":"36","author":"P-O Karlstr\u00f6m","year":"2018","unstructured":"Karlstr\u00f6m P-O, Holte J, Hadziosmanovic N, Rodriguez-Wallberg KA, Olofsson JI. Does ovarian stimulation regimen affect IVF outcome? A two-Centre, real-world retrospective study using predominantly cleavage-stage, single embryo transfer. Reprod BioMed Online. 2018;36(1):59\u201366. https:\/\/doi.org\/10.1016\/j.rbmo.2017.10.102.","journal-title":"Reprod BioMed Online"},{"key":"768_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1477-7827-8-137","volume":"8","author":"GH Trew","year":"2010","unstructured":"Trew GH, Brown AP, Gillard S, Blackmore S, Clewlow C, O'Donohoe P, et al. In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review. Reprod Biol Endocrinol. 2010;8:137.","journal-title":"Reprod Biol Endocrinol"},{"key":"768_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejogrb.2018.04.006","volume":"225","author":"SC Braam","year":"2018","unstructured":"Braam SC, de Bruin JP, Buisman E, Brandes M, Nelen W, Smeenk JMJ, et al. Treatment strategies and cumulative live birth rates in WHO-II ovulation disorders. Eur J Obstet Gynecol Reprod Biol. 2018;225:84\u20139. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.04.006.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"768_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJMoa0803072","volume":"360","author":"BA Malizia","year":"2009","unstructured":"Malizia BA, Hacker MR, Penzias AS. Cumulative live-birth rates after in vitro fertilization. N Engl J Med. 2009;360(3):236\u201343. https:\/\/doi.org\/10.1056\/NEJMoa0803072.","journal-title":"N Engl J Med"},{"issue":"11","key":"768_CR39","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1093\/humrep\/deh501","volume":"19","author":"M Germond","year":"2004","unstructured":"Germond M, Urner F, Chanson A, Primi MP, Wirthner D, Senn A. What is the most relevant standard of success in assisted reproduction?: the cumulated singleton\/twin delivery rates per oocyte pick-up: the CUSIDERA and CUTWIDERA. Hum Reprod. 2004;19(11):2442\u20134. https:\/\/doi.org\/10.1093\/humrep\/deh501.","journal-title":"Hum Reprod"},{"issue":"12","key":"768_CR40","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1093\/humrep\/dev263","volume":"30","author":"A Maheshwari","year":"2015","unstructured":"Maheshwari A, McLernon D, Bhattacharya S. Cumulative live birth rate: time for a consensus? Hum Reprod. 2015;30(12):2703\u20137. https:\/\/doi.org\/10.1093\/humrep\/dev263.","journal-title":"Hum Reprod"},{"issue":"5","key":"768_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3109\/09513590.2011.633128","volume":"28","author":"KF B\u00fchler","year":"2012","unstructured":"B\u00fchler KF, Fischer R. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case\u2013control study. Gynecol Endocrinol. 2012;28(5):345\u201350. https:\/\/doi.org\/10.3109\/09513590.2011.633128.","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"768_CR42","first-page":"284","volume":"1","author":"M Ludwig","year":"2004","unstructured":"Ludwig M, B\u00fchler K, Diedrich K, Felberbaum RE, Rabe T. Wirksamkeit von rekombinantem humanem FSH im Vergleich zu urin\u00e4rem hMG nach Downregulation im langen Protokoll-Eine Analyse von 24.764 ART-Zyklen in Deutschland. J Reprod Med Endocrinol. 2004;1(4):284\u20138.","journal-title":"J Reprod Med Endocrinol"},{"issue":"08","key":"768_CR43","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1055\/s-2001-17250","volume":"123","author":"S-J Pak","year":"2001","unstructured":"Pak S-J, Warlich J, van Rooij TNM. RecDate-eine IT-L\u00f6sung f\u00fcr die Dokumentation und Qualit\u00e4tssicherung reproduktionsmedizinischer Behandlungen. Zentralbl Gynakol. 2001;123(08):482\u20136. https:\/\/doi.org\/10.1055\/s-2001-17250.","journal-title":"Zentralbl Gynakol"},{"key":"768_CR44","unstructured":"2007\u20132012 [cited October 2020]. Available from: https:\/\/www.deutsches-ivf-register.de\/jahrbuch-archiv.php. Accessed Oct 2020."},{"issue":"5","key":"768_CR45","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.fertnstert.2013.06.049","volume":"100","author":"M Huber","year":"2013","unstructured":"Huber M, Hadziosmanovic N, Berglund L, Holte J. Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem. Fertil Steril. 2013;100(5):1270\u20136. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.06.049.","journal-title":"Fertil Steril"},{"key":"768_CR46","volume-title":"Biosimilar medicines: marketing authorisation","author":"EMA","year":"2019","unstructured":"EMA. Biosimilar medicines: marketing authorisation 2019 Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/biosimilar-medicines-marketing-authorisation."},{"issue":"3","key":"768_CR47","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/humrep\/dev336","volume":"31","author":"DJ McLernon","year":"2016","unstructured":"McLernon DJ, Maheshwari A, Lee AJ, Bhattacharya S. Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178,898 women. Hum Reprod. 2016;31(3):572\u201381. https:\/\/doi.org\/10.1093\/humrep\/dev336.","journal-title":"Hum Reprod"},{"issue":"3","key":"768_CR48","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.fertnstert.2014.05.020","volume":"102","author":"B Luke","year":"2014","unstructured":"Luke B, Brown MB, Wantman E, Stern JE, Baker VL, Widra E, et al. A prediction model for live birth and multiple births within the first three cycles of assisted reproductive technology. Fertil Steril. 2014;102(3):744\u201352. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.05.020.","journal-title":"Fertil Steril"},{"issue":"4","key":"768_CR49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1037\/1082-989X.9.4.403","volume":"9","author":"DF McCaffrey","year":"2004","unstructured":"McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9(4):403\u201325. https:\/\/doi.org\/10.1037\/1082-989X.9.4.403.","journal-title":"Psychol Methods"},{"issue":"1","key":"768_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355. https:\/\/doi.org\/10.1093\/biomet\/70.1.41.","journal-title":"Biometrika"},{"issue":"3","key":"768_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/sim.3782","volume":"29","author":"BK Lee","year":"2010","unstructured":"Lee BK, Lessler J, Stuart EA. Improving propensity score weighting using machine learning. Stat Med. 2010;29(3):337\u201346. https:\/\/doi.org\/10.1002\/sim.3782.","journal-title":"Stat Med"},{"issue":"25","key":"768_CR52","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697.","journal-title":"Stat Med"},{"issue":"4","key":"768_CR53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40471-017-0131-y","volume":"4","author":"JW Jackson","year":"2017","unstructured":"Jackson JW, Schmid I, Stuart EA. Propensity scores in Pharmacoepidemiology: beyond the horizon. Curr Epidemiol Rep. 2017;4(4):271\u201380. https:\/\/doi.org\/10.1007\/s40471-017-0131-y.","journal-title":"Curr Epidemiol Rep"},{"issue":"1","key":"768_CR54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.rbmo.2018.09.019","volume":"38","author":"E Bosch","year":"2019","unstructured":"Bosch E, Bulletti C, Copperman AB, Fanchin R, Yarali H, Petta CA, et al. How time to healthy singleton delivery could affect decision-making during infertility treatment: a Delphi consensus. Reprod BioMed Online. 2019;38(1):118\u201330. https:\/\/doi.org\/10.1016\/j.rbmo.2018.09.019.","journal-title":"Reprod BioMed Online"},{"issue":"5","key":"768_CR55","first-page":"195","volume":"17","author":"V Blumenauer","year":"2020","unstructured":"Blumenauer V, Czeromin U, Fehr D, Fiedler K, Gnoth C, Kr\u00fcssel J-S, et al. Deutsches IVF-Register (D\u00b7I\u00b7R) 2019. J Reproduktionsmed Endokrinol. 2020;17(5):195\u2013259.","journal-title":"J Reproduktionsmed Endokrinol"},{"issue":"8","key":"768_CR56","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10815-017-0952-0","volume":"34","author":"MS Christianson","year":"2017","unstructured":"Christianson MS, Shoham G, Tobler KJ, Zhao Y, Monseur B, Leong M, et al. Use of various gonadotropin and biosimilar formulations for in vitro fertilization cycles: results of a worldwide web-based survey. J Assist Reprod Genet. 2017;34(8):1059\u201366. https:\/\/doi.org\/10.1007\/s10815-017-0952-0.","journal-title":"J Assist Reprod Genet"},{"issue":"5","key":"768_CR57","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmx017","volume":"23","author":"CB Lambalk","year":"2017","unstructured":"Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23(5):560\u201379. https:\/\/doi.org\/10.1093\/humupd\/dmx017.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"768_CR58","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.rbmo.2014.07.002","volume":"29","author":"R Orvieto","year":"2014","unstructured":"Orvieto R. GnRH agonist versus GnRH antagonist in ovarian stimulation: has the ongoing debate resolved? Reprod BioMed Online. 2014;29(5):647\u20139. https:\/\/doi.org\/10.1016\/j.rbmo.2014.07.002.","journal-title":"Reprod BioMed Online"},{"issue":"3","key":"768_CR59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.rbmo.2014.05.007","volume":"29","author":"D Grow","year":"2014","unstructured":"Grow D, Kawwass JF, Kulkarni AD, Durant T, Jamieson DJ, Macaluso M. GnRH agonist and GnRH antagonist protocols: comparison of outcomes among good-prognosis patients using national surveillance data. Reprod BioMed Online. 2014;29(3):299\u2013304. https:\/\/doi.org\/10.1016\/j.rbmo.2014.05.007.","journal-title":"Reprod BioMed Online"},{"issue":"9","key":"768_CR60","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1093\/humrep\/dei086","volume":"20","author":"G Griesinger","year":"2005","unstructured":"Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German national IVF registry. Hum Reprod. 2005;20(9):2373\u20135. https:\/\/doi.org\/10.1093\/humrep\/dei086.","journal-title":"Hum Reprod"},{"issue":"6","key":"768_CR61","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.fertnstert.2005.02.011","volume":"83","author":"BC Fauser","year":"2005","unstructured":"Fauser BC, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril. 2005;83(6):1607\u201311. https:\/\/doi.org\/10.1016\/j.fertnstert.2005.02.011.","journal-title":"Fertil Steril"},{"issue":"2","key":"768_CR62","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s1472-6483(10)60957-1","volume":"11","author":"R Marci","year":"2005","unstructured":"Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M. GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reprod BioMed Online. 2005;11(2):189\u201393. https:\/\/doi.org\/10.1016\/s1472-6483(10)60957-1.","journal-title":"Reprod BioMed Online"},{"key":"768_CR63","first-page":"279","volume":"6","author":"D\u00b7I\u00b7R","year":"2019","unstructured":"D\u00b7I\u00b7R. Deutsches IVF-Register (D\u00b7I\u00b7R) 2018. J Reproduktionsmed Endokrinol. 2019;6:279\u2013315.","journal-title":"J Reproduktionsmed Endokrinol"},{"key":"768_CR64","first-page":"1","volume":"15","author":"D\u00b7I\u00b7R","year":"2018","unstructured":"D\u00b7I\u00b7R. Deutches IVF Register (D\u00b7I\u00b7R) 2017. J Reproduktionsmed Endokrinol. 2018;15:1\u201356.","journal-title":"J Reproduktionsmed Endokrinol"},{"key":"768_CR65","first-page":"1","volume":"14","author":"D\u00b7I\u00b7R","year":"2017","unstructured":"D\u00b7I\u00b7R. Deutches IVF Register (D\u00b7I\u00b7R) 2016. J Reproduktionsmed Endokrinol. 2017;14:1\u201356.","journal-title":"J Reproduktionsmed Endokrinol"},{"issue":"4","key":"768_CR66","doi-asserted-by":"publisher","first-page":"e0175985","DOI":"10.1371\/journal.pone.0175985","volume":"12","author":"R Wang","year":"2017","unstructured":"Wang R, Lin S, Wang Y, Qian W, Zhou L. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: a systematic review and meta-analysis. PLoS One. 2017;12(4):e0175985. https:\/\/doi.org\/10.1371\/journal.pone.0175985.","journal-title":"PLoS One"},{"key":"768_CR67","first-page":"CD001750","volume":"4","author":"HG Al-Inany","year":"2016","unstructured":"Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"768_CR68","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.fertnstert.2020.03.029","volume":"114","author":"CA Witz","year":"2020","unstructured":"Witz CA, Daftary GS, Doody KJ, Park JK, Seifu Y, Yankov VI, et al. Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. Fertil Steril. 2020;114(2):321\u201330. https:\/\/doi.org\/10.1016\/j.fertnstert.2020.03.029.","journal-title":"Fertil Steril"},{"issue":"6","key":"768_CR69","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3109\/09513590.2014.892066","volume":"30","author":"JC Arce","year":"2014","unstructured":"Arce JC, Klein BM, La Marca A. The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin. Gynecol Endocrinol. 2014;30(6):444\u201350. https:\/\/doi.org\/10.3109\/09513590.2014.892066.","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"768_CR70","first-page":"370","volume":"31","author":"P Drakopoulos","year":"2016","unstructured":"Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31(2):370\u20136.","journal-title":"Hum Reprod"},{"issue":"4","key":"768_CR71","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.fertnstert.2018.04.039","volume":"110","author":"NP Polyzos","year":"2018","unstructured":"Polyzos NP, Drakopoulos P, Parra J, Pellicer A, Santos-Ribeiro S, Tournaye H, et al. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization\/intracytoplasmic sperm injection: a multicenter multinational analysis including approximately 15,000 women. Fertil Steril. 2018;110(4):661\u201370 e1. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.04.039.","journal-title":"Fertil Steril"},{"issue":"1","key":"768_CR72","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/humrep\/dez258","volume":"35","author":"MB Ratna","year":"2020","unstructured":"Ratna MB, Bhattacharya S, Abdulrahim B, McLernon DJ. A systematic review of the quality of clinical prediction models in in vitro fertilisation. Hum Reprod. 2020;35(1):100\u201316. https:\/\/doi.org\/10.1093\/humrep\/dez258.","journal-title":"Hum Reprod"},{"issue":"9","key":"768_CR73","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1093\/humrep\/dey263","volume":"33","author":"JA Leijdekkers","year":"2018","unstructured":"Leijdekkers JA, Eijkemans MJC, van Tilborg TC, Oudshoorn SC, McLernon DJ, Bhattacharya S, et al. Predicting the cumulative chance of live birth over multiple complete cycles of in vitro fertilization: an external validation study. Hum Reprod. 2018;33(9):1684\u201395. https:\/\/doi.org\/10.1093\/humrep\/dey263.","journal-title":"Hum Reprod"},{"issue":"3","key":"768_CR74","doi-asserted-by":"publisher","first-page":"S493","DOI":"10.1016\/j.fertnstert.2013.07.349","volume":"100","author":"P Arvis","year":"2013","unstructured":"Arvis P, Guivarc'h-Leveque A, Colella C, Lehert P. A life birth predictive model after in vitro fertilization (IVF) may have a fair discrimination: results of a multicenter external validation based on 15039 IVF cycles. Fertil Steril. 2013;100(3):S493. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.07.349.","journal-title":"Fertil Steril"},{"issue":"4","key":"768_CR75","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmu003","volume":"20","author":"S Iliodromiti","year":"2014","unstructured":"Iliodromiti S, Kelsey TW, Wu O, Anderson RA, Nelson SM. The predictive accuracy of anti-M\u00fcllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update. 2014;20(4):560\u201370. https:\/\/doi.org\/10.1093\/humupd\/dmu003.","journal-title":"Hum Reprod Update"},{"key":"768_CR76","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejogrb.2018.04.039","volume":"225","author":"SSE Alson","year":"2018","unstructured":"Alson SSE, Bungum LJ, Giwercman A, Henic E. Anti-m\u00fcllerian hormone levels are associated with live birth rates in ART, but the predictive ability of anti-m\u00fcllerian hormone is modest. Eur J Obstet Gynecol Reprod Biol. 2018;225:199\u2013204. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.04.039.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"768_CR77","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.fertnstert.2017.10.021","volume":"109","author":"R Tal","year":"2018","unstructured":"Tal R, Seifer DB, Wantman E, Baker V, Tal O. Antim\u00fcllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. Fertil Steril. 2018;109(2):258\u201365. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.10.021.","journal-title":"Fertil Steril"},{"issue":"3","key":"768_CR78","first-page":"1","volume":"10","author":"E Patorno","year":"2013","unstructured":"Patorno E, Grotta A, Bellocco R, Schneeweiss S. Propensity score methodology for confounding control in health care utilization databases. Epidemiol Biostat Public Health. 2013;10(3):1\u20136.","journal-title":"Epidemiol Biostat Public Health"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-021-00768-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-021-00768-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-021-00768-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T07:03:30Z","timestamp":1623827010000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-021-00768-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1186\/s12958-021-00768-3","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KFB has received honoraria or consultation fees from Merck KGaA, Darmstadt, Germany, Ferring, Bayer, Stiftung Endometriose Forschung and Takeda, and is on a member of an advisory board for Merck KGaA, Darmstadt, Germany.RF has received honoraria from Merck KGaA, Darmstadt, Germany and affiliates for lectures.PV, AA, ER, EB and TDH are employees of Merck KGaA, Darmstadt, Germany.WB is an employee of Merck Serono GmbH, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany.SG was an employee of Merck KGaA, Darmstadt, Germany when this analysis was conducted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}